Speaker illustration

Doctor David Kallend

The Medicines Company, Zurich (Switzerland)

David Kallend is Chief Medical Officer of The Medicines Company (MDCO), which he joined in 2013. At MDCO, he has overseen the development of various cardiovascular therapies including inclisiran, his current focus. Previously David was with Schering AG in Germany, Zeneca / AstraZeneca in the UK and Roche AG in Switzerland where he worked predominantly in global drug development, in-licensing and medical affairs. He has extensive experience of global regulatory interactions within the cardiovascular and diagnostic therapy areas including in the USA, Europe and Asia-Pacific regions. While at AZ, his final role was the Lead Global Brand Physician for CRESTOR®. At Roche, as Group Medical Director, he worked on the strategy for the development and launch of several new therapies in the cardiovascular and metabolic franchise including dalcetrapib. He holds an MBBS degree from the University of London, UK and trained in surgery at the Royal Postgraduate Medical School in London.

Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial

Event: ESC CONGRESS 2019

Topic: Drug therapy

Session: Lipids / Cardiovascular risk prediction / Life style

Thumbnail

The ORION Program - Rationale and emerging evidence

Event: ESC CONGRESS 2019

Topic: Trial Design

Session: The ORION Program - What to look for in ORION-11

Thumbnail

This platform is supported by

logo Novo Nordisk